Galmed Pharma (GLMD) Adds to NASH-Frenzy Gains

September 22, 2016 3:28 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

NASH stock Galmed Pharma (NASDAQ: GLMD) is pushing to the highs of the session. Shares are up 16.8% to $5.42, and up 43% since Tuesday when Allergan (NASDAQ: AGN) agreed to acquire Tobira Therapeutics (NASDAQ: TBRA) at a huge premium.

This afternoon, Galmed announced that it has signed an Investigator-Initiated Clinical Trial Agreement with the University of California, San Diego, School of Medicine.

Speculators are buying Galmed Pharma and other NASH stocks on their scarcity value and potential takeovers.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Momentum Movers, Rumors, Trader Talk

Related Entities

Definitive Agreement

Add Your Comment